QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)

Editas Medicine - EDIT Stock Forecast, Price & News

$11.26
-0.27 (-2.34%)
(As of 02/3/2023 05:47 PM ET)
Add
Compare
Today's Range
$10.89
$11.93
50-Day Range
$7.81
$11.53
52-Week Range
$7.70
$21.59
Volume
2.59 million shs
Average Volume
2.10 million shs
Market Capitalization
$774.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.86

Editas Medicine MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
48.6% Upside
$16.73 Price Target
Short Interest
Bearish
32.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
0.61mentions of Editas Medicine in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$17,481 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.08) to ($2.90) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

201st out of 1,029 stocks

Biological Products, Except Diagnostic Industry

35th out of 169 stocks

EDIT stock logo

About Editas Medicine (NASDAQ:EDIT) Stock

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

EDIT Stock News Headlines

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks? (EDIT)
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.
Why Editas Medicine's Shares Jumped This Week
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Is Editas Medicine Stock a Buy Now?
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Editas Medicine (NASDAQ:EDIT) Price Target Cut to $7.00
Editas Medicine (NASDAQ:EDIT) PT Raised to $7.00 at SVB Leerink
Analyst Expectations for Editas Medicine's Future
See More Headlines
Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

EDIT Company Calendar

Last Earnings
11/08/2021
Today
2/03/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EDIT
Fax
N/A
Employees
264
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.73
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+49.7%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
15 Analysts

Profitability

Net Income
$-192,500,000.00
Net Margins
-784.32%
Pretax Margin
-784.32%

Debt

Sales & Book Value

Annual Sales
$25.54 million
Book Value
$8.09 per share

Miscellaneous

Free Float
67,869,000
Market Cap
$774.24 million
Optionable
Optionable
Beta
1.87

Key Executives

  • Gilmore O’Neill
    President, Chief Executive Officer & Director
  • Harry R. Gill
    Senior Vice President-Operations
  • Michelle RobertsonMichelle Robertson
    Chief Financial Officer & Treasurer
  • Mark S. Shearman
    Chief Scientific Officer & Executive VP
  • Mei Baisong
    Chief Medical Officer & Senior Vice President













EDIT Stock - Frequently Asked Questions

Should I buy or sell Editas Medicine stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 2 sell ratings, 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View EDIT analyst ratings
or view top-rated stocks.

What is Editas Medicine's stock price forecast for 2023?

15 brokers have issued twelve-month price targets for Editas Medicine's stock. Their EDIT share price forecasts range from $7.00 to $36.00. On average, they predict the company's share price to reach $16.73 in the next year. This suggests a possible upside of 44.1% from the stock's current price.
View analysts price targets for EDIT
or view top-rated stocks among Wall Street analysts.

How have EDIT shares performed in 2023?

Editas Medicine's stock was trading at $8.87 at the start of the year. Since then, EDIT shares have increased by 30.9% and is now trading at $11.61.
View the best growth stocks for 2023 here
.

When is Editas Medicine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our EDIT earnings forecast
.

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) posted its quarterly earnings results on Monday, November, 8th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.24. The business earned $6.20 million during the quarter, compared to the consensus estimate of $4.92 million. Editas Medicine had a negative net margin of 784.32% and a negative trailing twelve-month return on equity of 41.33%. The company's revenue for the quarter was down 90.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.12 earnings per share.

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

When did Editas Medicine IPO?

(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by many different retail and institutional investors. Top institutional shareholders include Exchange Traded Concepts LLC (0.13%), Green Alpha Advisors LLC (0.09%), McGuire Investment Group LLC (0.02%), ProShare Advisors LLC (0.02%), Elmwood Wealth Management Inc. (0.02%) and Sigma Planning Corp (0.02%). Insiders that own company stock include Bruce Eaton, Charles Albright, Cynthia Collins, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson.
View institutional ownership trends
.

How do I buy shares of Editas Medicine?

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $11.61.

How much money does Editas Medicine make?

Editas Medicine (NASDAQ:EDIT) has a market capitalization of $798.30 million and generates $25.54 million in revenue each year. The company earns $-192,500,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis.

How many employees does Editas Medicine have?

The company employs 264 workers across the globe.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The official website for the company is www.editasmedicine.com. The company can be reached via phone at (617) 401-9000 or via email at mark.mullikin@editasmed.com.

This page (NASDAQ:EDIT) was last updated on 2/3/2023 by MarketBeat.com Staff